Related references
Note: Only part of the references are listed.Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Timothy Kendall et al.
LIVER INTERNATIONAL (2019)
Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma
Samantha Sarcognato et al.
VIRCHOWS ARCHIV (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma
Michele Simbolo et al.
SCIENTIFIC REPORTS (2018)
Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss
Kento Misumi et al.
HISTOPATHOLOGY (2017)
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
L. M. Kats et al.
LEUKEMIA (2017)
Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas
Masayuki Akita et al.
MODERN PATHOLOGY (2017)
Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes
Michael John Kerins et al.
MOLECULAR AND CELLULAR BIOLOGY (2017)
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms
Shahab Babakoohi et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma
Akimasa Hayashi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
Juliana Andrici et al.
MEDICINE (2016)
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Supriya K. Saha et al.
CANCER DISCOVERY (2016)
Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours
Qiu Rao et al.
HISTOPATHOLOGY (2015)
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
ONCOLOGIST (2015)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Andrew X. Zhu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
Jau-Yu Liau et al.
MODERN PATHOLOGY (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
Michele Simbolo et al.
ONCOTARGET (2014)
Isocitrate dehydrogenase mutations in leukemia
Anna Sophia McKenney et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma
Motohiro Arai et al.
BRAIN TUMOR PATHOLOGY (2012)
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
Mina Komuta et al.
HEPATOLOGY (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment
Ya-yong Li et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2011)
Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens
Matthias Preusser et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Proposal of progression model for intrahepatic cholangiocarcinoma: Clinicopathologic differences between hilar type and peripheral type
Shinichi Aishima et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States
Katherine A. McGlynn et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Do mitochondria regulate cellular iron homeostasis through citric acid and haem production Implications for cancer and other diseases
S Johnson
MEDICAL HYPOTHESES (2003)
Share Paper
